Corcept Therapeutics Inc (CORT) 2.75 $CORT
Cortendo AB: Interim Report, Q2 and H1 2014
Business Wire - Tue Aug 26, 2:14AM CDT
Cortendo AB (OSE:CORT)
Investors look to Lighten Up on Shares of Corcept Therapeutics, Shares Down 8.8% (CORT)
Comtex SmarTrend(R) - Thu Aug 21, 12:42PM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 8.8% to $2.69 on 1.1x average daily volume. Corcept Therapeutics has traded 248,000 shares thus far today, vs. average volume of 226,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's 0.5%) and underperformed the S&P 500 (-8.8% to the S&P's 0.3%) during today's trading.
Earnings Estimates Moving Higher for Corcept Therapeutics (CORT): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 7:43AM CDT
Corcept Therapeutics could be a solid choice for investors, as it witnessed solid activity on the earnings estimate revision front and also has a favorable Zacks Rank.
Cortendo AB: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting
Business Wire - Tue Aug 12, 1:30AM CDT
Cortendo AB (OSE:CORT) today announced that the first patient has been enrolled into the Phase 3 SONICS trial, i.e., "Study Of NormoCort In Cushing's Syndrome."
Cortendo names Matthew Pauls as CEO
M2 - Thu Aug 07, 4:57AM CDT
Biopharmaceutical company Cortendo AB (OSE:CORT) today announced that it has appointed Matthew Pauls as president and chief executive officer, effective 25 August 2014.
Cortendo Appoints Matthew Pauls as Chief Executive Officer
Business Wire - Thu Aug 07, 2:00AM CDT
Cortendo AB (OSE:CORT) announces the appointment of Matthew Pauls as President and Chief Executive Officer effective Monday, August 25, 2014.
Corcept Therapeutics Announces Second Quarter 2014 Financial Results and Provides Corporate Update
Marketwire - Tue Aug 05, 3:06PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT)
Corcept Therapeutics to Announce Second Quarter Financial Results and Host Conference Call
Marketwire - Tue Jul 29, 3:07PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 5, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Corcept Therapeutics Down 5.4%, Shares Slide into the Red (CORT)
Comtex SmarTrend(R) - Mon Jul 28, 12:43PM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 5.4% to $2.28 on 1.0x average daily volume. Corcept Therapeutics has traded 296,000 shares thus far today, vs. average volume of 287,000 shares per day. The stock has underperformed the Dow (-5.4% to the Dow's 0.2%) and underperformed the S&P 500 (-5.4% to the S&P's 0.1%) during today's trading.
/ CORRECTION - Corcept Therapeutics
Marketwire - Fri Jun 20, 3:15PM CDT
In the news release, "New Research on Corcept's Korlym(R) for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014," issued Thursday, June 19, 2014 by Corcept Therapeutics (NASDAQ: CORT), we are advised by the company that the session schedule has now been updated to reflect accurate presentation times with poster numbers added. Complete corrected text follows.
New Research on Corcept's Korlym(R) for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014
Marketwire - Thu Jun 19, 8:02AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today announced that new clinical research on Korlym(R) (mifepristone) will be presented at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014).
Global Pituitary ACTH Hypersecretion (Cushing's Disease) Clinical Trials Report 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3btnds/pituitary_acth) has announced the addition of the "Pituitary ACTH Hypersecretion (Cushing's Disease) Global Clinical Trials Review, H1, 2014" report to their offering. Pituitary ACTH Hypersecretion (Cushing's Disease) Global Clinical Trials Review, H1, 2014" provides data on the Pituitary ACTH Hypersecretion (Cushing's Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pituitary ACTH Hypersecretion (Cushing's Disease). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pituitary ACTH Hypersecretion (Cushing's Disease). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Pituitary ACTH Hypersecretion (Cushing's Disease) Therapeutics Clinical Trials - Novartis AG - Corcept Therapeutics Incorporated - Isis Pharmaceuticals, Inc. - Laboratoires Pierre Fabre SA - Cortendo Invest AB - Eunice Kennedy Shriver National Institute of Child Health and Human Development - National Center for Research Resources - University of Wurzburg - UCLA's Jonsson Comprehensive Cancer Center - Erasmus MC - Massachusetts General Hospital - Assistance Publique - Hopitaux de Paris - Hiroshima University Hospital - Universita di Padova - Samsung Medical Center For more information visit http://www.researchandmarkets.com/research/3b...itary_acth
Hot Stock: Corcept Therapeutics, Shares Gain 13.5% (CORT)
Comtex SmarTrend(R) - Fri Mar 28, 11:41AM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 13.5% to $4.38 on 1.2x average daily volume. Corcept Therapeutics has traded 641,000 shares thus far today, vs. average volume of 540,000 shares per day. The stock has outperformed the Dow (13.5% to the Dow's 0.7%) and outperformed the S&P 500 (13.5% to the S&P's 0.7%) during today's trading.
Will Corcept Therapeutics (CORT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:45AM CDT
Will Corcept Therapeutics (CORT) Continue to Surge Higher?
Corcept Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 05, 8:02AM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2013.
Corcept Therapeutics Up 9.5%, Shares Break Through Resistance (CORT)
Comtex SmarTrend(R) - Tue Mar 04, 10:14AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 9.5% to $3.69 on 1.0x average daily volume. Corcept Therapeutics has traded 464,000 shares thus far today, vs. average volume of 457,000 shares per day. The stock has outperformed the Dow (9.5% to the Dow's 1.2%) and outperformed the S&P 500 (9.5% to the S&P's 1.3%) during today's trading.
TransCanada Files 2013 Annual Disclosure Documents
Marketwire Canada - Fri Feb 21, 3:26PM CST
TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada) has today filed with Canadian securities authorities:
Traders Get Bullish on Shares of Corcept Therapeutics, Shares Up 6.9% (CORT)
Comtex SmarTrend(R) - Wed Feb 12, 11:41AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 6.9% to $3.25 on 2.8x average daily volume. Corcept Therapeutics has traded 1.3 million shares thus far today, vs. average volume of 473,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's -0.2%) and outperformed the S&P 500 (6.9% to the S&P's 0.0%) during today's trading.
Cortendo AB: Interim Report, Q2 and H1 2014
Business Wire - Tue Aug 26, 2:14AM CDT
Cortendo AB (OSE:CORT)
Investors look to Lighten Up on Shares of Corcept Therapeutics, Shares Down 8.8% (CORT)
Comtex SmarTrend(R) - Thu Aug 21, 12:42PM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 8.8% to $2.69 on 1.1x average daily volume. Corcept Therapeutics has traded 248,000 shares thus far today, vs. average volume of 226,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's 0.5%) and underperformed the S&P 500 (-8.8% to the S&P's 0.3%) during today's trading.
Earnings Estimates Moving Higher for Corcept Therapeutics (CORT): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 7:43AM CDT
Corcept Therapeutics could be a solid choice for investors, as it witnessed solid activity on the earnings estimate revision front and also has a favorable Zacks Rank.
Cortendo AB: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting
Business Wire - Tue Aug 12, 1:30AM CDT
Cortendo AB (OSE:CORT) today announced that the first patient has been enrolled into the Phase 3 SONICS trial, i.e., "Study Of NormoCort In Cushing's Syndrome."
Cortendo names Matthew Pauls as CEO
M2 - Thu Aug 07, 4:57AM CDT
Biopharmaceutical company Cortendo AB (OSE:CORT) today announced that it has appointed Matthew Pauls as president and chief executive officer, effective 25 August 2014.
Cortendo Appoints Matthew Pauls as Chief Executive Officer
Business Wire - Thu Aug 07, 2:00AM CDT
Cortendo AB (OSE:CORT) announces the appointment of Matthew Pauls as President and Chief Executive Officer effective Monday, August 25, 2014.
Corcept Therapeutics Announces Second Quarter 2014 Financial Results and Provides Corporate Update
Marketwire - Tue Aug 05, 3:06PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT)
Corcept Therapeutics to Announce Second Quarter Financial Results and Host Conference Call
Marketwire - Tue Jul 29, 3:07PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 5, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Corcept Therapeutics Down 5.4%, Shares Slide into the Red (CORT)
Comtex SmarTrend(R) - Mon Jul 28, 12:43PM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 5.4% to $2.28 on 1.0x average daily volume. Corcept Therapeutics has traded 296,000 shares thus far today, vs. average volume of 287,000 shares per day. The stock has underperformed the Dow (-5.4% to the Dow's 0.2%) and underperformed the S&P 500 (-5.4% to the S&P's 0.1%) during today's trading.
/ CORRECTION - Corcept Therapeutics
Marketwire - Fri Jun 20, 3:15PM CDT
In the news release, "New Research on Corcept's Korlym(R) for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014," issued Thursday, June 19, 2014 by Corcept Therapeutics (NASDAQ: CORT), we are advised by the company that the session schedule has now been updated to reflect accurate presentation times with poster numbers added. Complete corrected text follows.
New Research on Corcept's Korlym(R) for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014
Marketwire - Thu Jun 19, 8:02AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today announced that new clinical research on Korlym(R) (mifepristone) will be presented at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014).
Global Pituitary ACTH Hypersecretion (Cushing's Disease) Clinical Trials Report 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3btnds/pituitary_acth) has announced the addition of the "Pituitary ACTH Hypersecretion (Cushing's Disease) Global Clinical Trials Review, H1, 2014" report to their offering. Pituitary ACTH Hypersecretion (Cushing's Disease) Global Clinical Trials Review, H1, 2014" provides data on the Pituitary ACTH Hypersecretion (Cushing's Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pituitary ACTH Hypersecretion (Cushing's Disease). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pituitary ACTH Hypersecretion (Cushing's Disease). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Pituitary ACTH Hypersecretion (Cushing's Disease) Therapeutics Clinical Trials - Novartis AG - Corcept Therapeutics Incorporated - Isis Pharmaceuticals, Inc. - Laboratoires Pierre Fabre SA - Cortendo Invest AB - Eunice Kennedy Shriver National Institute of Child Health and Human Development - National Center for Research Resources - University of Wurzburg - UCLA's Jonsson Comprehensive Cancer Center - Erasmus MC - Massachusetts General Hospital - Assistance Publique - Hopitaux de Paris - Hiroshima University Hospital - Universita di Padova - Samsung Medical Center For more information visit http://www.researchandmarkets.com/research/3b...itary_acth
Hot Stock: Corcept Therapeutics, Shares Gain 13.5% (CORT)
Comtex SmarTrend(R) - Fri Mar 28, 11:41AM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 13.5% to $4.38 on 1.2x average daily volume. Corcept Therapeutics has traded 641,000 shares thus far today, vs. average volume of 540,000 shares per day. The stock has outperformed the Dow (13.5% to the Dow's 0.7%) and outperformed the S&P 500 (13.5% to the S&P's 0.7%) during today's trading.
Will Corcept Therapeutics (CORT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:45AM CDT
Will Corcept Therapeutics (CORT) Continue to Surge Higher?
Corcept Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 05, 8:02AM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2013.
Corcept Therapeutics Up 9.5%, Shares Break Through Resistance (CORT)
Comtex SmarTrend(R) - Tue Mar 04, 10:14AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 9.5% to $3.69 on 1.0x average daily volume. Corcept Therapeutics has traded 464,000 shares thus far today, vs. average volume of 457,000 shares per day. The stock has outperformed the Dow (9.5% to the Dow's 1.2%) and outperformed the S&P 500 (9.5% to the S&P's 1.3%) during today's trading.
TransCanada Files 2013 Annual Disclosure Documents
Marketwire Canada - Fri Feb 21, 3:26PM CST
TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada) has today filed with Canadian securities authorities:
Traders Get Bullish on Shares of Corcept Therapeutics, Shares Up 6.9% (CORT)
Comtex SmarTrend(R) - Wed Feb 12, 11:41AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 6.9% to $3.25 on 2.8x average daily volume. Corcept Therapeutics has traded 1.3 million shares thus far today, vs. average volume of 473,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's -0.2%) and outperformed the S&P 500 (6.9% to the S&P's 0.0%) during today's trading.
